Table 2.
The antimicrobial susceptibility results of the clinical strains and transconjugants (mg l−1)
|
Strain |
MIC (mg l−1) |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
IMP |
MEM |
ETP |
CTX |
FEP |
LEV |
CIP |
AMK |
GEN |
ATM |
TGC |
CST |
|
|
YML0508 |
0.5 |
0.25 |
4 |
0.25 |
0.25 |
1 |
1 |
1 |
1 |
0.125 |
0.5 |
0.125 |
|
YML0508-C |
0.5 |
0.25 |
1.5 |
0.38 |
0.25 |
4 |
1 |
1 |
0.5 |
0.125 |
0.25 |
0.06 |
|
WSD411 |
4 |
4 |
>64 |
≥32 |
≥256 |
≥32 |
≥512 |
≥256 |
≥512 |
≥256 |
2 |
0.06 |
|
WSD411-C |
0.5 |
0.125 |
1 |
0.125 |
0.25 |
0.19 |
0.25 |
1 |
0.25 |
0.125 |
0.5 |
0.06 |
|
WSD2016 |
0.5 |
0.25 |
8 |
0.75 |
1 |
0.5 |
0.5 |
1 |
1 |
0.125 |
0.25 |
0.125 |
|
WSD2016-C |
0.5 |
0.125 |
0.5 |
0.19 |
0.25 |
0.25 |
0.25 |
1 |
0.5 |
0.25 |
0.125 |
0.125 |
|
WSD2080 |
0.5 |
0.5 |
4 |
0.25 |
0.5 |
0.5 |
0.5 |
1 |
1 |
0.125 |
0.25 |
0.125 |
|
WSD2080-C |
0.5 |
0.125 |
0.38 |
0.064 |
0.25 |
2 |
1 |
1 |
0.5 |
0.125 |
0.25 |
0.06 |
|
EC600 |
0.125 |
0.06 |
0.006 |
0.094 |
0.125 |
0.25 |
0.25 |
1 |
0.5 |
0.125 |
0.125 |
0.06 |
YML0508/WSD411/WSD2016/WSD2080-C: strain EC600 acquired plasmid from strain YML0508/WSD411/WSD2016/WSD2080 by conjugation. IMP: imipenem; MEM: meropenem; ETP: ertapenem; CTX: cefotaxime; FEP: cefepime; CPS: cefperazone/sulbactam; LEV: levofloxacin; CIP: ciprofloxacin; ATM: aztreonam; TGC: tigecycline; CST: colistin. The shaded area represents the antimicrobial susceptibility results of clinical strains. The MICs for IMP, MEM, ETP, TGC and CST were determined using the broth microdilution method following the guidelines from the Clinical and Laboratory Standard Institute (CLSI). MICs were interpreted according to CLSI breakpoints for K. pneumoniae. Susceptibility to other antimicrobial agents was tested via etest (AB bioMérieux) or broth microdilution.